Silke Raffegerst

Christian Ellinger2
Susanne Wilde2
Barbara Mosetter2
Slavoljub Milosevic2
2Christian Ellinger
2Susanne Wilde
2Barbara Mosetter
2Slavoljub Milosevic
Learn More
MOTIVATION Adoptive T cell therapies based on introduction of new T cell receptors (TCRs) into patient recipient T cells is a promising new treatment for various kinds of cancers. A major challenge, however, is the choice of target antigens. If an engineered TCR can cross-react with self-antigens in healthy tissue, the side-effects can be devastating. We(More)
  • Carina Wehner, Christian Ellinger, Silke Raffegerst, Susanne Wilde, Barbara Mosetter, Judith Eckl +6 others
  • 2014
In recent years, activation of the patient's immune system to defend against tumors was demonstrated to be a promising alternative strategy to classical cancer treatments. Dendritic cells (DCs) can present antigens on MHC-II and-I leading to the activation of CD4 + or CD8 + T cells, respectively. Stimulated CD4 + T cells act as helper cells for cytotoxic(More)
Depending on the mechanisms by which cancer develops and the strategies tumors use to escape the immune system, cancer therapies are more or less successful. A combination of different therapeutic agents, such as den-dritic cell (DC) vaccines loaded with tumor antigens and adoptive transfer of tumor-specific T-cells, may enhance the chances of effective(More)
  • 1